Will AstraZeneca stock avoid deeper losses as sellers dominate the short-term trend?

Traders Union
All News
Financial News
AstraZeneca slides 1.32% to GBX12,444

Highlights

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a targeted lung cancer therapy, expanding its oncology portfolio.
This substantial upfront outlay signals AstraZeneca’s strategic focus on long-term cancer pipeline innovation despite immediate cash impact.
AstraZeneca shares are under persistent bearish pressure, trading below major moving averages, with a short-term forecast range of GBX11,579 to GBX13,308 and high risk of further downside.

Oncology portfolio expands as $600 million lung cancer deal pressures cash

AstraZeneca has agreed to pay Dizal Pharmaceutical $600 million upfront to secure global rights to a drug targeting a specific type of lung cancer, according to Finance Yahoo. This significant upfront investment will reduce immediate cash reserves while expanding AstraZeneca's oncology pipeline, reflecting a strategic commitment to long-term therapeutic innovation. Although the deal enhances the company’s portfolio prospects, today's price action has remained under broader selling pressure.

Bearish momentum sustained as indicators confirm oversold conditions

On the technical side, price remains below the MA-20, MA-50, and MA-200 moving averages. The Ichimoku Kijun currently stands at GBX12,979 and serves as the nearest resistance. Among indicators, the Moving Average Convergence Divergence (MACD) signals strong sell, while the Average Directional Index (ADX) indicates a sell bias. The Relative Strength Index (RSI) is at 29.34, and both Stochastic RSI and Commodity Channel Index (CCI) confirm oversold conditions. Bull/Bear Power reflects persistent seller dominance, and the Awesome Oscillator is neutral, showing no clear counter-move.

Downside risks dominate as forecast range narrows

In the next two to three trading days, the price is expected to remain within the GBX11,579 to GBX13,308 forecast range. The probability of a downward extension is very high, while upward movement remains very unlikely. The baseline scenario envisages consolidation within this corridor. A bullish outcome would require a breakout above resistance at the Kijun level, while a bearish scenario could see the price targeting the lower part of the expected volatility band.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s stock under clear technical pressure below all key moving averages. The recent $600 million deal confirms management’s focus on oncology but puts near-term strain on cash reserves. Downside risk persists given strong sell signals across leading indicators. "Until GBX12,979 is reclaimed, the price is likely to stay weak — I remain defensive short term."

Earlier, analysts noted that AstraZeneca shares faced persistent downside risk amid negative technical momentum and pipeline setbacks. The latest acquisition expands AstraZeneca's oncology pipeline but does not alter the prevailing technical bias, and traders should watch for any decisive move above or below the current GBX12,979 resistance and GBX11,579 support to signal a shift in trend direction.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.